MorphoSys now listed at Nasdaq
Annual Financial Results 2017
First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!
We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.
Find out more about our therapeutic programs and project advancements in our Annual Report 2016.
Hematological cancers
affect adults and children alike.
MorphoSys is developing several blood cancer programs.
Solid tumors can occur in
several organs of the human body.
MorphoSys and its partners are working on a broad portfolio of new therapies.
MorphoSys's vision
23/04/2018
MorphoSys Announces Closing of Nasdaq IPO through an ADS Offering and...
18/04/2018
Ad hoc: MorphoSys Resolves a Capital Increase to Implement the Offering of...
09/04/2018
Ad hoc: MorphoSys Announces Launch of American Depositary Shares (ADS)...
06/04/2018
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) for the Treatment...
22/03/2018
Ad hoc: MorphoSys Files Registration Statement in the United States for a...
